CSL Limited (CSLLY)
(Delayed Data from OTC)
$93.85 USD
+0.93 (1.00%)
Updated Nov 4, 2024 02:18 PM ET
4-Sell of 5 4
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CSLLY 93.85 +0.93(1.00%)
Will CSLLY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CSLLY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CSLLY
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
CSLLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Other News for CSLLY
CSL (CMXHF) Gets a Buy from UBS
CSL (CMXHF) Gets a Buy from Jarden
Citi Reaffirms Their Buy Rating on CSL (CMXHF)
Macquarie Keeps Their Buy Rating on CSL (CMXHF)
Travere Therapeutics, CSL Vifor announce Swissmedic approval of FILSPARI